Immunome To Present Poster Highlighting Preclinical Evaluation Of IM-1021, A ROR1-Targeted Antibody Drug Conjugate, At The 36th EORTC-NCI-AACR Symposium
Express News | Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Health Care Stocks Moving In Tuesday's After-Market Session
Immunome CFO Sells Shares Valued at Over $230,000
Express News | Immunome to Present Updated Results for Ringside Phase 2 Trial of Al102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (Esmo) Congress 2024
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Wedbush analyst David Nierengarten maintains $Immunome(IMNM.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a success rate of 43.5% and a
Immunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Leerink Partners Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $38
Leerink Partners analyst Andrew Berens maintains $Immunome(IMNM.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 40.4% and
Buy Rating Affirmed on Immunome: Promising Clinical Trials and Strategic Growth Prospects
Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target
Immunome Is Maintained at Overweight by Piper Sandler
Immunome Price Target Cut to $23.00/Share From $27.00 by Piper Sandler
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
TD Cowen analyst Tyler Van Buren maintains $Immunome(IMNM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.6% and a total average return of -0.6% over the past
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $23
Piper Sandler analyst Biren Amin maintains $Immunome(IMNM.US)$ with a buy rating, and adjusts the target price from $27 to $23.According to TipRanks data, the analyst has a success rate of 41.1% and
Immunome Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)
Immunome GAAP EPS of -$0.60 Misses by $0.17, Revenue of $2.37M Beats by $0.5M
Express News | Immunome Inc : Piper Sandler Cuts Target Price to $23 From $27